Abstract
The article presents the results of clinical studies on the comparative effectiveness of different forms of the drug Cytovir-3 (syrup and powder for solution for oral administration) and Immunal l in the treatment of acute respiratory viral infections in children. It was found in a comparative randomized parallel-group study of 90 children aged two through six years that the drug Cytovir-3 (syrup and powder) became active faster than the comparison drug Immunal, providing normalization of body temperature, reduction of some manifestations of the general intoxication and respiratory syndrome, as well as elevated levels of serum immunoglobulin A. All drugs in the study had an equally normalizing effect on the content of peripheral blood leukocytes and erythrocyte sedimentation rates. The compared products were characterized by good tolerability, lack of side effects and high preventive efficacy against respiratory disease complications. Cytovir-3 drugs (syrup and powder for oral solution) and Immunal had similar ratios of clinical and laboratory safety, efficacy and tolerability. Both products can be used for the treatment of respiratory diseases in children aged two through six years.
Highlights
В статье представлены материалы клинического исследования, посвященного изучению сравнительной эффективности различных лекарственных форм препаратов Цитовир-3 и Иммунал при лечении острых респираторных вирусных инфекций у детей
Petersburg, 197376, Russian Federation The article presents the results of clinical studies on the comparative effectiveness of different forms of the drug Cytovir-3 and Immunal l in the treatment of acute respiratory viral infections in children
It was found in a comparative randomized parallel-group study of 90 children aged two through six years that the drug Cytovir-3 became active faster than the comparison drug Immunal, providing normalization of body temperature, reduction of some manifestations of the general intoxication and respiratory syndrome, as well as elevated levels of serum immunoglobulin A
Summary
В статье представлены материалы клинического исследования, посвященного изучению сравнительной эффективности различных лекарственных форм препаратов Цитовир-3 (сироп и порошок для приготовления раствора для приема внутрь) и Иммунал при лечении острых респираторных вирусных инфекций у детей. По соотношению клинико-лабораторной эффективности, безопасности и переносимости Цитовир-3 и Иммунал сопоставимы и могут применяться для лечения респираторной патологии у детей от 2 до 6 лет. Сравнительная клинико-лабораторная эффективность препаратов для патогенетического лечения острых респираторных вирусных инфекций. Сytovir-3 drugs (syrup and powder for oral solution) and Immunal had similar ratios of clinical and laboratory safety, efficacy and tolerability Both products can be used for the treatment of respiratory diseases in children aged two through six years. Этих препаратов вирус способен формировать невосприимчивость, другие дают побочные реакции и не разре- фармакологической композиции Цитовир-3 в медициншены к применению у детей младшего возраста. (ОРИ) и гриппом [16]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
